Cargando…
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies. GSK2110183 and GSK2141795 are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to human clinical studies. Both compounds are selectiv...
Autores principales: | Dumble, Melissa, Crouthamel, Ming-Chih, Zhang, Shu-Yun, Schaber, Michael, Levy, Dana, Robell, Kimberly, Liu, Qi, Figueroa, David J., Minthorn, Elisabeth A., Seefeld, Mark A., Rouse, Meagan B., Rabindran, Sridhar K., Heerding, Dirk A., Kumar, Rakesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076210/ https://www.ncbi.nlm.nih.gov/pubmed/24978597 http://dx.doi.org/10.1371/journal.pone.0100880 |
Ejemplares similares
-
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015) -
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2019) -
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011) -
MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013) -
Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)